for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-VBL Presents Positive Interim Data From Pivotal Study In Ovarian Cancer

June 1 (Reuters) - Vascular Biogenics Ltd:

* VBL PRESENTS POSITIVE INTERIM DATA FROM THE OVAL PHASE 3 PIVOTAL STUDY IN OVARIAN CANCER AT THE ASCO20 ANNUAL MEETING, SHOWING 58% OR HIGHER OBJECTIVE RESPONSE RATE

* VASCULAR BIOGENICS LTD - OVERALL CA-125 RESPONSE RATE IN FIRST 60 RANDOMIZED EVALUABLE PATIENTS IS 53%

* VASCULAR BIOGENICS LTD -OVAL STUDY IS PLANNED TO ENROLL APPROXIMATELY 400 PATIENTS Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up